research A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib
Palbociclib generally maintains or improves quality of life in advanced breast cancer patients.
Search
for
Sort by
Research
30 / 1000+ results research Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.
research CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane‐induced alopecia
CDK4/6 inhibitors can protect hair cells from chemotherapy damage.
research Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
research Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
research Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
research Optimizing Scalp Cooling: (Ultra)Structural Follicular Characteristic and Restorative Advances
Improving hair health and managing conditions can enhance scalp cooling effectiveness in preventing hair loss during chemotherapy.
research Rare Case of Alopecia: Alopecia Neoplastica
A rare case of hair loss was linked to breast cancer spreading to the scalp, but treatment was effective.
research Prostaglandin E2 prevents radiotherapy-induced alopecia by attenuating transit amplifying cell apoptosis through promoting G1 arrest
Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair cells.
research Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
research Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.
research EFFECTS OF A LOW‐DOSE DESOGESTREL‐ETHINYLESTRADIOL COMBINATION ON HIRSUTISM, ANDROGENS AND SEX HORMONE BINDING GLOBULIN IN WOMEN WITH A POLYCYSTIC OVARY SYNDROME
Low-dose oral contraceptives reduced hair growth and testosterone levels in women with polycystic ovary syndrome.
research Contraception hormonale et cancer du sein : Une question de contexte
Birth control pills slightly increase the risk of breast cancer, especially if used before the first full-term pregnancy.
research Hormonal contraceptives: pharmacology tailored to women's health
New hormonal contraceptives are safer, have fewer side effects, and offer health benefits for women.
research Bicalutamide
research Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial
Birth control pills combined with bicalutamide are more effective at reducing excessive hair growth in women with PCOS than birth control pills alone.
research Contraceptive implants considered 'safe'
Some birth control pills increase blood clot risk; use them for specific conditions only.
research Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).
Further testing of paclitaxel poliglumex for this cancer treatment is not justified.
research Progestogens with Antiandrogenic Properties
research Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
research Management of Alopecia Due to Cancer Therapies
The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.
research Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study.
The treatment effectively reduced hair growth and was safe for patients with PCOS, but it needs better bleeding control.
research Changes in the serum metabolomics of polycystic ovary syndrome before and after compound oral contraceptive treatment
COC treatment improves hormone and metabolic levels in PCOS patients.
research Bicalutamide: A potential new oral antiandrogenic drug for female pattern hair loss
Bicalutamide may be a promising alternative treatment for female pattern hair loss.
research Abstract P5-11-11: A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA)
Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
research Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome
Elagolix did not effectively treat polycystic ovary syndrome.
research Efficacy and tolerability of oral bicalutamide in forty postmenopausal women with female pattern hair loss: a retrospective study
Bicalutamide may improve hair growth in postmenopausal women with mild side effects.
research Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women
The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
research Результаты применения комбинированных оральных контрацептивов с дроспиреноном и финастерида у женщин с синдромом поликистозных яичников без метаболических нарушений
Both finasteride and drospirenone treatments improved symptoms and increased pregnancy rates in women with polycystic ovary syndrome.